Sawtooth Solutions LLC Cuts Stock Position in Oncorus, Inc. (NASDAQ:ONCR)
Sawtooth Solutions LLC Cuts Stock Position in Oncorus, Inc. (NASDAQ:ONCR)
Sawtooth Solutions LLC lessened its stake in shares of Oncorus, Inc. (NASDAQ:ONCR – Get Rating) by 52.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,748 shares of the company's stock after selling 40,588 shares during the quarter. Sawtooth Solutions LLC's holdings in Oncorus were worth $31,000 at the end of the most recent quarter.
根據最近向美國證券交易委員會（SEC）提交的 13F 表格，鋸齒齒輪解決方案有限責任公司（NASDAQ：ONCR-獲得評級）在第三季度減少了 52.5％ 的股份。該基金在本季度賣出 40,588 股股票後，擁有該公司股票的 36,748 股股份。鋸齒解決方案有限責任公司在安科洛斯的持股價值為 31,000 美元在最近一個季度結束。
Several other large investors have also modified their holdings of ONCR. Millennium Management LLC purchased a new stake in shares of Oncorus during the second quarter worth approximately $476,000. Renaissance Technologies LLC grew its holdings in Oncorus by 1,144.9% during the first quarter. Renaissance Technologies LLC now owns 175,532 shares of the company's stock worth $312,000 after acquiring an additional 161,432 shares during the period. Private Advisor Group LLC acquired a new position in Oncorus during the first quarter worth $112,000. Bank of New York Mellon Corp grew its holdings in Oncorus by 106.6% during the first quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock worth $218,000 after acquiring an additional 62,985 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Oncorus by 35.1% during the second quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after acquiring an additional 30,668 shares during the period. Hedge funds and other institutional investors own 63.69% of the company's stock.
其他一些大型投資者也修改了他們對 ONCR 的持有權。千禧管理有限責任公司在第二季度購買了 Oncorus 股份的新股份，價值約為 476,000 美元。文藝復興技術有限責任公司在第一季度增長了 1,144.9％ 在安科魯斯的持有量。文藝復興科技有限責任公司現在擁有該公司股票的 175,532 股價值 312,000 美元後，在此期間額外收購 161,432 股股份。私人顧問集團有限責任公司在第一季度收購了 Oncorus 的新職位，價值 112,000 美元。紐約梅隆銀行在第一季度增加了 106.6％ 在安科魯斯的持有量。紐約梅隆銀行在期內另外購入 62,985 股股份後，現擁有該公司股票的 122,047 股，價值 218,000 美元。最後，在第二季度，高盛集團在安科洛斯的持有量增長了 35.1％。期內，高盛集團股份有限公司現在擁有該公司股票的 117,925 股，價值 148,000 美元。對沖基金和其他機構投資者擁有公司股票的 63.69％。
Oncorus Stock Up 3.0 %
安科洛斯股票上升 3.0%
ONCR opened at $0.28 on Friday. The company has a quick ratio of 4.97, a current ratio of 4.97 and a debt-to-equity ratio of 0.24. The firm has a market cap of $7.36 million, a P/E ratio of -0.10 and a beta of 2.24. Oncorus, Inc. has a 52 week low of $0.27 and a 52 week high of $5.76. The business's fifty day simple moving average is $0.54 and its 200 day simple moving average is $1.01.
首都鐵路上週五以 0.28 美元開盤。該公司的快速比率為 4.97，流動比率為 4.97，債務與權益比率為 0.24。該公司的市值為 736 萬美元，市盈率為 -0.10，測試版為 2.24。安科魯斯擁有 52 周低點 0.27 美元，52 周高點為 5.76 美元。該企業的五十天簡單移動平均線為 0.54 美元，其 200 天的簡單移動平均線為 1.01 美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of research analysts recently weighed in on the company. Chardan Capital lowered Oncorus from a "buy" rating to a "neutral" rating in a report on Wednesday, November 30th. HC Wainwright lowered Oncorus from a "buy" rating to a "neutral" rating in a report on Tuesday, December 6th. Finally, Piper Sandler lowered Oncorus from an "overweight" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.00 in a report on Wednesday, November 30th.
一些研究分析師最近稱重該公司。Chardan 資本在 11 月 30 日（週三）的報告中將昂可洛斯從「買入」評級降低到「中立」評級。韋賴特在 12 月 6 日（星期二）的一份報告中，HC 溫賴特將安科洛斯從「買入」評級降至「中性」評級。最後，派珀·桑德勒將安科洛斯從「超重」評級降低到「中立」評級，並在 11 月 30 日（星期三）的一份報告中將公司的目標價格從 6.00 美元降至 2.00 美元。
Insider Activity at Oncorus
安可洛斯的內幕活動
In related news, major shareholder James E. Flynn sold 99,718 shares of the stock in a transaction on Monday, December 19th. The stock was sold at an average price of $0.29, for a total transaction of $28,918.22. Following the sale, the insider now owns 332,725 shares of the company's stock, valued at $96,490.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 118,704 shares of company stock valued at $35,123 over the last quarter. Insiders own 15.90% of the company's stock.
在相關消息中，主要股東詹姆斯·弗林於 12 月 19 日（星期一）在一次交易中出售了該股 99,718 股。該股票以 0.29 美元的平均價格出售，總交易額為 28,918.22 美元。出售後，內幕人士現在擁有該公司股票的 332,725 股，價值 96,490.25 美元。該交易在與 SEC 的文件中披露，可以通過以下方式訪問 此超連結。與上個季度相比，內部人員總共出售了 118,704 股公司股票，價值為 35,123 美元。業內人士擁有公司股票的 15.90%。
Oncorus Profile
安康洛斯配置文件
(Get Rating)
(取得評分)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Oncorus, Inc 是一家臨床階段生物製藥公司，致力於為癌症患者開發病毒免疫療法。該公司的主要候選產品是 ONCR-177，這是一種基於其單純皰疹病毒 1 型平台的臨床內施用的病毒免疫療法，該平台正在用於治療各種癌症的 I 期臨床試驗中。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取有關安科洛斯（ONCR）的研究報告
- 市場節拍：評論中的一周
- 這些鋼鐵製造商應該在您的 2023 觀察名單中佔有一席之地
- 通貨膨脹冷卻，S&P 500 現在去哪裡
- 辛塔斯用運營槓桿擊敗通貨膨脹
- 您購買 Palantir 的決定可能只是時間問題
Want to see what other hedge funds are holding ONCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oncorus, Inc. (NASDAQ:ONCR – Get Rating).
想看看還有哪些對沖基金持有 ONCR？ 訪問 Holdingschannel.com 以獲取有關安科魯斯公司（NASDAQ：ONCR-獲取評分）的最新 13 樓文件和內幕交易。
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oncorus 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Oncorus 及相關公司的最新新聞和分析師評級的簡要每日摘要。